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Dysregulated JAK2 expression 
by TrkC promotes metastasis 
potential, and EMT program of 
metastatic breast cancer
Min Soo Kim1, Joon Jeong2, Jeongbeob Seo3, Hae-Suk Kim4, Seong-Jin Kim5 & Wook Jin1,6
Metastatic breast cancers are aggressive tumors associated with high levels of epithelial-mesenchymal 
transition (EMT) markers, activation of IL6/JAK2/STAT3 and PI3K/AKT pathways for cell growth, 
mobility, invasion, metastasis, and CSC status. We identified a new molecular and functional network 
present in metastasis that regulates and coordinates with TrkC. Inhibition of SOCS3-mediated JAK2 
degradation by TrkC increases total JAK2/STAT3 expression, and then leads to upregulation of Twist-1 
through activation of JAK2/STAT3 cascade. Also, TrkC increases secretion and expression of IL-6, 
suggesting that this autocrine loop generated by TrkC maintains the mesenchymal state by continued 
activation of the JAK2/STAT3 cascade and upregulation of Twist expression. Moreover, TrkC interacts 
with the c-Src/Jak2 complex, which increases Twist-1 and Twist-2 levels via regulation of JAK2/STAT3 
activation and JAK2/STAT3 expression. Furthermore, TrkC enhances metastatic potential of breast 
cancer via induction of EMT by upregulating Twist-1 and Twist-2. Additionally, TrkC significantly 
enhances the ability of breast cancer cells to form pulmonary metastases and primary tumor formation. 
Unexpectedly, we found that TrkC expression and clinical breast tumor pathological phenotypes 
show significant correlation. These findings suggest that TrkC plays a central role in tumorigenicity, 
metastasis, and self-renewal traits of metastatic breast cancer.
Metastatic breast cancers have shown enriched gene signatures that are responsible for cell-cell adhesion and 
markers linked to stem cell function and the EMT program1,2. By activating a usually dormant EMT program, 
carcinoma cells can acquire phenotypes that have therapeutic resistance, stem cell-like characteristics that are 
required for the execution of most steps of the invasion–metastasis cascade2,3. In addition, EMT-inducing tran-
scription factors such as Snail4–6, Slug7,8, SIP19,10, Goosecoid11,12, FOXC213, Twist-114, and Twist-215 can promote 
this transition.
The recent discovery of cancer stem cells (CSCs) in neoplastic tissues suggests a key role of stem cells in tum-
origenesis and metastasis. Importantly, the induction of EMT by EMT-inducing transcription factors can sponta-
neously convert both normal and neoplastic non-stem cells into a stem-like state. In addition, acquisition of CSC 
subpopulations, which are present in some human breast tumors, is associated with disease aggressiveness and 
poor survival2,16,17. Moreover, CSCs are more enriched in metastatic breast cancer cells. Furthermore, the IL-6/
JAK2/Stat3 pathway was preferentially active in metastatic breast cancer cells, and inhibition of JAK2 decreased 
the number of cells and blocked the growth of xenografts18.
TrkC belongs to the tropomyosin-related kinase (Trk) family of neurotrophin receptors that primarily reg-
ulates growth, differentiation, and survival of neurons19. Trk family members have also been found in several 
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non-neural cell types, such as brain cancer, soft tissue cancer, and lung cancer20–23. In addition, recent studies 
have identified several somatic mutations in TrkC implicated in breast (R678Q)24,25, lung (V307L, H677Y, L336Q, 
R721F)25,26, gastric (T149R)25, colorectal (G608S, I695V, R731Q, K732T, L760I)27, and pancreatic (G608S, E322K, 
H599Y)28–30 cancers. These results suggest that TrkC may have high mutation rates in human cancer genomes 
and can be potentially activated by somatic mutations. Furthermore, TrkC may function as a dominant cancer 
gene that is activated by genetic rearrangements in cancer. Although TrkC mutations have been identified in a 
number of human tumors, it is unclear whether deregulated TrkC is oncogenic. We recently demonstrated that 
TrkC expression activates mitogenic and survival pathways in breast cancer cells. We have also shown that TrkC 
rendered cells resistant to TGF-β tumor suppressor activity, suggesting that suppression of the TGF-β tumor 
suppressor pathway may contribute to TrkC-mediated tumorigenicity31. Furthermore, we recently demonstrated 
that c-Src activation by TrkC induces activation of the PI3K-AKT pathway32. These findings indicate that TrkC 
activation/overexpression may play a crucial role in the initiation, progression, and metastasis of breast cancer 
and other tumors. However, the signaling mechanisms that induce and maintain tumorigenicity and metastasis of 
breast cancer by TrkC have remained poorly understood. In this study, we show that TrkC was highly expressed in 
metastatic breast cancer and that TrkC may contribute to the conversion of breast cancer cells into a more aggres-
sive and chemoresistant form via acquirement of mesenchymal characteristics and metastatic ability. Thus, our 
study uncovers and functionally dissects a new molecular and functional network present in cancer metastasis 
mediated by TrkC.
Results
TrkC expression was correlated with pathological phenotypes of breast cancer. Although our 
previous studies have already demonstrated that TrkC plays a crucial role in initiation, progression, and metas-
tasis of cancer by inducing activation of the PI3K-AKT cascade32 and Twist-1 expression33, TrkC expression 
patterns have not been well characterized in human breast cancer. To assess whether TrkC was an important 
mediator of the metastatic potential of breast cancer, we first examined TrkC expression in a panel of established 
metastatic and non-metastatic human tumor cell lines. TrkC was highly expressed in basal-like breast cancer cell 
lines (MDA-MB-435, MDA-MB-231, Hs578T, SUM149, SUM159, and BT549) than in luminal cancer cell lines 
(BT474 and T47D). Immortalized human mammary epithelial cells (HMLEs) also expressed low to undetect-
able TrkC levels (Figure S1a). Next, we examined whether some of breast cancer cell lines used in our studies 
carry TrkC mutations. We conducted the bioinformatical analysis of our unpublished whole transcriptome data 
generated from human breast cancer cell lines. The sequencing analysis showed only synonymous variants in 
ZR-75HS578T cells (Table S1).
Based on the above observations, we speculated whether TrkC correlated with breast cancer pathology in 
breast cancer patients. Interestingly, TrkC expression was elevated in 14 out of 17 tumors (82%) relative to their 
corresponding patient-matched normal tissue samples (Fig. 1a). We next performed an in silico analysis of 
TrkC transcript levels in the tissues of 2,136 breast cancer patients of the Curtis dataset34 and 473 breast cancer 
patients of the UNC dataset1 at Oncomine. Strikingly, TrkC expression was more highly upregulated in basal 
and claudin-low breast cancers than in other breast cancer subtypes (Fig. 1b). These results suggested that TrkC 
expression was closely correlated with the TrkC gene signature derived from breast cancer subtypes.
Metastatic breast cancers are aggressive, chemoresistant tumors characterized by lineage plasticity and a 
unique molecular profile. Intersestingly, they also form a distinct subtype closely related to a novel subset of 
receptor-negative breast cancers (claudin-low) characterized by loss of genes involved in cell-cell adhesion1. 
Based on these observations, we evaluated whether TrkC expression correlated with a triple-negative subtype 
of breast cancer. TrkC expression was significantly elevated in triple-negative tumor tissues compared to normal 
tissue samples (Fig. 1c). Also, results from a large clinical microarray study showed that TrkC expression was 
significantly upregulated in triple-negative subtypes relative to other subtypes (Fig. 1d). Moreover, we evalu-
ated TrkC expression in a series of 59 breast cancer samples by immunohistochemistry. We found a significant 
correlation between TrkC expression and pathological phenotypes. Normal breast tissue samples demonstrated 
weak immunoreactivity to an anti-TrkC antibody; however, high TrkC levels were detected in infiltrating ductal 
and metastatic carcinoma samples (Fig. 1e). Furthermore, results from a large clinical microarray study showed 
that patients with tumors exhibiting high TrkC expression levels exhibit poorer survival outcomes relative to 
patients with tumors expressing low TrkC levels (Fig. 1f). Our observation indicated that patients with higher 
TrkC expression have worse prognosis relative to those that have low TrkC expression and it might play a crucial 
role in progression and metastasis of breast cancer.
TrkC induces Twist by inducing activation and expression of JAK2/STAT3. To investigate the rela-
tionship between JAK2/STAT3 cascade and TrkC-induced Twist-1 expression, we first assessed the effects of a 
Trk inhibitor and JAK2 inhibitor on JAK2/STAT3 activation and JAK2/STAT3/Twist-1 expression. The inhibition 
of TrkC activation by K252a in Hs578T and SUM149 cells significantly reduced JAK2/STAT3 phosphorylation 
and Twist-1 expression. Interestingly, JAK2 and STAT3 expression levels were markedly reduced upon treatment 
with K252a (Fig. 2a). Also, the inhibition of JAK2 activation in Hs578T and SUM149 cells by the JAK2 inhibitor 
AG490 significantly reduced JAK2 and STAT3 phosphorylation and Twist-1 expression (Fig. 2b). However, JAK2 
and STAT3 expression levels were not significantly different after treatment with AG490. Moreover, the inhibition 
of TrkC activation by K252a in MCF10A-TrkC cells significantly reduced JAK2/STAT3 phosphorylation and 
Twist-1 expression. Also, JAK2 and STAT3 expression levels were markedly reduced upon treatment with K252a 
(Fig. 2c). These results suggest that the tyrosine kinase activity of TrkC correlates with increased expression levels 
of JAK2 and STAT3.
To examine whether TrkC knockdown could influence the activation of JAK2/STAT3/Twist cascade, we 
selected highly metastatic Hs578T and SUM149 cells stably expressing TrkC-shRNAs. As shown in Figure S1b, 
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TrkC-shRNA suppressed the expression of endogenous TrkC by 70%. Immunoblotting analysis revealed that 
JAK2 and STAT3 phosphorylation levels were markedly reduced in Hs578T and SUM149 TrkC-shRNA cells 
relative to those in control-shRNA cells. Interestingly, JAK2, STAT3, and Twist expression levels were also signif-
icantly reduced in Hs578T and SUM149 TrkC-shRNA cells (Fig. 2d).
To determine whether tyrosine kinase activity of TrkC was important for the induction of JAK2 and 
STAT3 expression, we ectopically expressed TrkC, TrkC K572N, or TrkC Yx3F mutants in MCF10A. In the 
activation-loop tyrosine triple mutant, TrkC Yx3F, all three activation-loop tyrosines were mutated to pheny-
lalanine. In mutant TrkC K572N, an ATP-binding site residue, lysine 572 (K), was substituted with asparag-
ine (N). Interestingly, JAK2/STAT3 expression and activation were markedly reduced in MCF10A-TrkC K572N 
and MCF10A-TrkC Yx3F compared to that in MCF10A-TrkC cells (Fig. 2e). Also, activation and expression of 
JAK2/STAT3 and Twist-1 expression were significantly increased in Hs578T and SUM149 TrkC-shRNA cells by 
ectopically-expressed TrkC, but not the TrkC K572N or TrkC Y3XF mutants (Fig. 2f). These findings suggest that 
Figure 1. Increased expression of TrkC in human breast carcinomas. (a) Relative levels of TrkC expression in 
normal or invasive breast carcinoma samples of 17 individual breast cancer patients. The expression was compared 
to that of healthy tissue, and the endogenous 18S mRNA level was measured as an internal control. A P value was 
considered to be significant in t-test. (b) The gene expression data were plotted as Box-and-whisker (Tukey) plots of 
mean TrkC expression levels in molecular subtypes of breast cancer patients. The signatures of TrkC level extracted 
from 2,136 Curtis and 473 UNC datasets and averaged for each tumor. Points below and above the whiskers are 
drawn as individual dots. A P value was considered to be significant in ANOVA. (c) Relative TrkC mRNA expression 
in seven individual normal human tissues or triple-negative breast carcinoma samples. The endogenous 18S mRNA 
level was measured as an internal control. A P value was considered to be significant in t-test. (d) The mean TrkC 
expression in other subtypes or triple-negative subtypes of human breast cancer patients from three publicly available 
data sets (Curtis, Gluck, and UNC datasets). The TrkC gene expression level was extracted from the dataset and 
averaged for each tumor. Points below and above the whiskers are drawn as individual dots. A P value was considered 
to be significant in t-test. (e) Pattern of TrkC expression in a series of 59 breast cancer samples. Representative 
immunohistochemical images of TrkC staining in normal human breast tissue, infiltrating duct carcinoma, and 
metastatic carcinoma in the lymph nodes (magnification: 200× ). (f) Patients were divided into those who expressed 
high and low TrkB levels, and their survival rates from a publicly available data set (UNC) were compared. The P value 
was calculated by a log-rank test.
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the tyrosine kinase activity of TrkC is required for JAK2/STAT3/Twist-1 induction. Furthermore, STAT3 mRNA 
expression was markedly reduced in response to TrkC knockdown (Figure S2a). Additionally, STAT3 luciferase 
activity was significantly decreased in SUM149 and Hs578T TrkC-shRNA cells relative to SUM149 and Hs578T 
control-shRNA cells (Figure S2b). These observations suggest that TrkC induces not only STAT3 phosphorylation 
but also STAT3 transcription. Because inhibition of JAK2 activity downregulates STAT3 phosphorylation but 
not STAT3 transcription, the transcriptional induction of STAT3 by TrkC is independent of the JAK2 signaling 
pathway.
TrkC induces JAK2 stabilization via inhibition of SOCS3-mediated ubiquitination. Because 
TrkC knockdown reduced JAK2 protein levels, we next examined whether TrkC transcriptionally regulated JAK2 
expression in SUM149 and Hs578T TrkC-shRNA cells. TrkC knockdown had no effect on JAK2 mRNA levels in 
SUM149 and Hs578T TrkC-shRNA cells (Fig. 3a). Interestingly, activation and expression of JAK2 and STAT3 
in Hs578T and SUM149 control-shRNA or TrkC-shRNA cells increased upon treatment with the proteasome 
inhibitor MG132 (Figure S3b), suggesting that TrkC post-translationally controls JAK2 protein stability. JAK2 
ubiquitination leads to degradation of the JAK2 protein; therefore, we investigated whether JAK2 stabilization by 
TrkC was mediated through the suppression of JAK2 ubiquitination. TrkC kinase-dead mutants (K572N, Y3XF) 
or K252a treatment significantly induced JAK2 ubiquitination compared to TrkC wild type (Fig. 3c and S3b). 
Furthermore, SOCS3 mediates the negative feedback inhibition of the JAK-STAT pathway. Specifically, induced 
SOCS3 protein can bind to JAK2 and suppress its activity by directly binding to its catalytic center and promoting 
its proteasomal degradation35. As shown in Fig. 3c, TrkC suppressed JAK2 ubiquitination, even in the presence 
of SOCS3.
Figure 2. TrkC regulates JAK2/STAT3 activity and directly regulates its downstream target. (a) Western blot 
analysis of the expression of P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in Hs578T and SUM149 cells 
with or without 50 nM K252a treatment for 16 hr. β -actin was used as a loading control. (b) Western blot analysis 
of the expression of P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in Hs578T and SUM149 cells with or 
without 15μ M AG490 (JAK2 inhibitor) treatment for 16 hr. β -actin was used as a loading control. (c) Western 
blot analysis of the expression of P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in MCF10A or MCF10A-
TrkC cells with or without 50 nM K252a treatment for 16 hr. β -actin was used as a loading control. (d) Western 
blot analysis of the expression of P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in Hs578T and SUM149 
control-shRNA or TrkC-shRNA cells. β -actin was used as a loading control. (e) Western blot analysis of the 
expression of P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in MCF10A, MCF10A-TrkC, or MCF10A-
TrkC kinase-dead mutant (K572N, Yx3F) cells. β -actin was used as a loading control. (f) Western blot analysis 
of the expression of the proteins P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 in SUM149 and Hs578T control-
shRNA or TrkC-shRNA cells after transfection of TrkC or TrkC kinase-dead mutant (K572N, Yx3F) constructs.
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We aimed to determine whether TrkC induced JAK2 activation by blocking the ability of SOCS3 to ubiquit-
inate and degrade JAK2 through the SOCS3-JAK2 complex formation. To test this possibility, we first examined 
whether TrkC directly interacts with JAK2. As shown in Fig. 3d, TrkC directly interacts with JAK2 but not with 
STAT3. However, TrkC kinase dead mutants and K252a treatment significantly reduced JAK2 interaction relative 
to TrkC wild type (Figure S3c).
To identify the JAK2 functional domain responsible for its interaction with TrkC, we used a series of JAK2 
deletion constructs. TrkC interacted with the tyrosine kinase domain of JAK2, but did not interact with the 
B41, SH2, or pseudokinase domain of JAK2 (Fig. 3e). We next investigated whether TrkC inhibited the forma-
tion of the SOCS3-JAK2 complex. As expected, TrkC coexpression significantly reduced the level of SOCS3 that 
associated with JAK2 (Fig. 3f). We next compared JAK2-SOCS3 complex formation in SUM149 and Hs578T 
TrkC-shRNA cells to that of control-shRNA cells. Relative to control-shRNA cells, endogenous levels of SOCS3 
that associated with JAK2 were dramatically increased in SUM149 and Hs578T TrkC-shRNA cells (Fig. 3g). 
These results indicate that TrkC binds to JAK2 and inhibits proteasome-mediated JAK2 degradation by blocking 
SOCS3-JAK2 complex formation, leading to increased JAK2 protein levels and activation of the JAK2/STAT3/
Twist-1 pathway.
TrkC increases IL-6 secretion and regulates the nuclear translocation of STAT3. The autocrine 
signal loop of IL-6 secreted by cancer cells induces STAT3 activation. Consequently, phosphorylated STAT3 trans-
locates to the nucleus and participates in DNA binding, which culminates in transactivation of genes involved in 
Figure 3. TrkC induces JAK2 stabilization by inhibiting SOCS3-mediated degradation of JAK2. (a) RT-PCR and 
western blot analysis of JAK2 expression in Hs578T and SUM149 control-shRNA or TrkC-shRNA cells. GAPDH and 
β -actin were used as loading controls. (b) Immunoblot analysis of whole-cell lysates and immunoprecipitates derived 
from 293T cells transfected with V5-TrkC, HA-Ubiquitin, and Myc-Jak2 constructs as indicated. (c) Immunoblot 
analysis of whole-cell lysates and immunoprecipitates derived from 293T cells transfected with V5-TrkC, HA-
Ubiquitin, Flag-SOCS3, and Myc-Jak2 constructs as indicated. (d) TrkC interacts with JAK2. Immunoblot analysis 
of whole-cell lysates and immunoprecipitates derived from 293T cells transfected with the V5-TrkC and Myc-Jak2 
constructs as indicated. (e) Identification of the JAK2 region responsible for TrkC interaction and immunoblot 
analysis of whole-cell lysates and immunoprecipitates derived from 293T cells transfected with the V5-TrkC and 
Myc-Jak2 deletion constructs as indicated. (f) Identification of the inhibition of SOCS3-JAK2 complex formation 
by TrkC and immunoblot analysis of whole-cell lysates and immunoprecipitates derived from 293T cells transfected 
with the V5-TrkC, Flag-SOCS3, and Myc-Jak2 constructs as indicated. (g) Identification of endogenous SOCS3-JAK2 
complexes in Hs578T and SUM149 control-shRNA or TrkC-shRNA cells.
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a number of cellular functions, such as proliferation, differentiation, survival, and maintenance of CSCs18,36–40. 
Therefore, we speculated that maintenance of JAK2/STAT3 activation might depend on the activation of the IL-6 
autocrine signaling loop by TrkC. To test this notion, we tested IL-6 levels secreted into the culture medium of 
Hs578T control-shRNA or TrkC-shRNA cells. Hs578T control-shRNA cells exhibited increased secretion of IL-6 
protein relative to Hs578T TrkC-shRNA cells (Fig. 4a).
We next tested whether TrkC expression in highly metastatic breast cancer cells may affect the expression of 
IL-6. To investigate this possibility, we compared IL-6 mRNA expression in highly metastatic breast cancer cells 
to that of normal or nontransformed cells. Relative to those in normal or nontransformed cells (HMLE, MCF7, or 
MCF10A), the levels of IL-6 were dramatically increased in highly metastatic breast cancer cells (MDA-MB-231, 
Hs578T, and SUM149), which highly express TrkC (Figure S1a and 4b). However, IL-6 mRNA expression in 
Hs578T control-shRNA cells was markedly increased relative to that in Hs578T TrkC-shRNA cells (Fig. 4c).
To further examine TrkC-mediated regulation of the JAK2/STAT3 pathway, we assessed JAK2 and STAT3 
activation following treatment of SUM149 and Hs578T control-shRNA cells or TrkC-shRNA cells with IL-6. 
IL-6 treatment dramatically increased JAK2 and STAT3 phosphorylation levels in SUM149 and Hs578T 
Figure 4. Increased secretion of IL-6 by TrkC correlates with increased nuclear translocation of STAT3. 
 (a) ELISA assay of IL-6 secretion by Hs578T control-shRNA or TrkC-shRNA cells (n = 3). Data are presented as 
mean ± standard error of the mean (SEM). (b) Expression levels of mRNA encoding IL-6 in basal-like breast cancer 
cells (MDA-MB-231, MDA-MB-435, Hs578T, and SUM149) and normal or nontransformed cells (HMLE, MCF7, 
or MCF10A breast cells). 18S mRNA was used to normalize variability in template loading. Data are presented as 
mean ± standard error of the mean (SEM). (c) Expression levels of mRNA encoding IL-6 in Hs578T control-shRNA 
or TrkC-shRNA cells. 18S mRNA was used to normalize variability in template loading. Data are presented as 
mean ± standard error of the mean (SEM). (d) Western blot analysis of the expression of P-JAK2, JAK2, P-STAT3, 
STAT3, and Twist-1 proteins in Hs578T and SUM149 control-shRNA or TrkC-shRNA cells with or without IL-6 
treatment. β -actin was used as a loading control. (e) Immunofluorescence staining of the nuclear translocation of 
STAT3 in Hs578T and SUM149 control-shRNA or TrkC-shRNA cells with or without IL-6 treatment. The green 
signal represents staining of the corresponding protein, while the blue signal represents DAPI nuclear DNA staining. 
(f) Expression levels of mRNA encoding Twist-1 and Twist-2 in Hs578T control-shRNA or TrkC-shRNA cells with 
or without IL-6 treatment. 18S mRNA was used to normalize variability in template loading. Data are presented 
as mean ± standard error of the mean (SEM). (g) Luciferase reporter assay of Twist-1 and Twist-2 in Hs578T 
control-shRNA or TrkC-shRNA cells with or without IL-6 treatment. Each bar represents the mean ± SEM of three 
experiments. Data are presented as mean ± standard error of the mean (SEM). Some of the bar graphs do not have 
visible error bars due to low values of standard error of the mean (SEM).
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control-shRNA cells relative to those in SUM149 and Hs578T TrkC-shRNA cells (Fig. 4d). Moreover, we exam-
ined whether enhanced IL-6 by TrkC actually activates the JAK2/STAT3 pathway. The levels of phospho-JAK2 
and STAT3 were more decreased in SUM149 and Hs578T control-shRNA or TrkC-shRNA cells after treatment 
with IL-6 neutralizing monoclonal antibody (Figure S4). These results suggest that enhanced IL-6 secretion by 
TrkC required maintenance of tumorigenicity and metastasis through activation of the JAK2/STAT3 and PI3K/
AKT pathways and Twist-1 expression. Furthermore, STAT3 nuclear translocation after IL-6 treatment was mark-
edly increased in SUM149 and Hs578T control-shRNA cells relative to SUM149 and Hs578T TrkC-shRNA cells 
(Fig. 4e). Additionally, the expression of JAK2, STAT3, Twist-1, and Twist-2 was markedly increased in Hs578T 
control-shRNA cells, but not in Hs578T TrkC-shRNA cells (Fig. 4d,f), which was correlated with the increased 
luciferase activity of Twist-1 and Twist-2 in Hs578T control-shRNA cells (Fig. 4g).
TrkC activates the JAK2/STAT3/Twist-1 axis directly and indirectly through c-Src. STAT3 activa-
tion by activated c-Src led to a significant increase in the levels of phospho-STAT3 and Twist-141. Also, in our pre-
vious study, endogenous TrkC interacted with c-Src, and the suppression of TrkC expression resulted in a marked 
repression of c-Src activation32. Therefore, we speculated that TrkC/c-Src and STAT3 might be functionally linked 
to the regulation of Twist-1 and Twist-2 expression. To test this, we evaluated whether c-Src in the presence of 
TrkC played a functional role in the induction of Twist by STAT3 activation. As shown in Fig. 5a, STAT3 phos-
phorylation levels were markedly decreased after treatment of SUM149 and Hs578T cells with SU6656, an inhib-
itor of c-Src. Twist-1 expression was markedly decreased as well; however, STAT3 expression was not affected 
by SU6656 treatment. Interestingly, we found that JAK2 phosphorylation and expression levels were markedly 
decreased after treating SUM149 and Hs578T cells with SU6656. To further examine whether c-Src regulated the 
activation and expression of JAK2 and STAT3, we first selected highly metastatic Hs578T and SUM149 cells stably 
expressing c-Src-shRNAs. As shown in Figure S5a, Hs578T and SUM149 c-Src-shRNA significantly suppressed 
the expression of endogenous c-Src. Also, immunoblotting analysis revealed that JAK2 and STAT3 phosphoryla-
tion levels were markedly reduced in Hs578T and SUM149 c-Src-shRNA cells relative to those in control-shRNA 
cells. Moreover, expression levels of JAK2 and Twist, but not STAT3, were significantly reduced in Hs578T and 
SUM149 c-Src-shRNA cells (Figure S5b), which was correlated with SU6656 treatment. Our results suggested 
that both TrkC and c-Src are required for the induction of JAK2/STAT3 expression and activation. Therefore, we 
next examined the possibility that TrkC/c-Src interacts with JAK2. As shown in Fig. 5b, TrkC/c-Src interacted 
with JAK2 after transient transfection. In addition, JAK2 interacted with TrkC in the absence of c-Src, indicating 
the direct binding of TrkC to JAK2. Also, endogenous TrkC interacted with endogenous c-Src/JAK2 in SUM149 
and Hs578T cells (Fig. 5c).
To confirm the role of c-Src in TrkC-mediated JAK2 activation, we overexpressed TrkC or c-Src in SYF 
cells derived from triple knockout mouse embryos lacking c-Src, Yes, and Fyn (Klinghoffer et al. 1999). To 
further determine whether TrkC-JAK2 formed a complex in the absence of c-Src, we transiently transfected 
SYF-TrkC and SYF-c-Src-TrkC cells with JAK2. As shown in Fig. 5d, TrkC-JAK2 complexes were detected in 
both c-Src-deficient SYF-TrkC and SYF-c-Src-TrkC cells. Next, we investigated whether TrkC induced activa-
tion of JAK2 without c-Src. The activation and expression of JAK2 were markedly increased in SYF-TrkC cells, 
and TrkC directly activated JAK2 via TrkC/JAK2 complex formation without c-Src (Fig. 5e). To further confirm 
the role of TrkC in the activation of the JAK2/STAT3 pathway, we examined the activation of JAK2/STAT3/
Twist-1 in SYF-TrkC cells and SYF-c-Src-TrkC cells. TrkC-mediated JAK2 and STAT3 phosphorylation levels and 
expression were markedly increased in SYF-TrkC cells. These levels were further enhanced in SYF-c-Src-TrkC 
cells, suggesting that TrkC/c-Src or TrkC synergistically induced JAK2/STAT3 phosphorylation. Consistent with 
these results, Twist-1 and Twist-2 expression was markedly increased when TrkC and c-Src were co-expressed 
(Fig. 5f,g). Moreover, Hs578T TrkC-shRNA cells demonstrated lower Twist-1 and Twist-2 mRNA levels than 
Hs578T cells treated with SU6656 (Fig. 5h). Furthermore, Twist-1 and Twist-2 luciferase activity in Hs578T 
control-shRNA and TrkC-shRNA cells were slightly reduced after SU6656 treatment (Figure S6a). However, 
Twist-1 and Twist-2 luciferase activity was markedly increased in SYF-TrkC cells and SYF-c-Src-TrkC cells 
(Figure S6b). Taken together, our results suggest that TrkC can activate the JAK2/STAT3/Twist-1 axis directly and 
indirectly through c-Src.
TrkC enhances metastatic potential of breast cancer through induction of EMT program. 
During cancer pathogenesis, a transdifferentiation program known as EMT is activated, thus enabling cells to exe-
cute multiple steps of the invasion-metastasis cascade. EMT refers to a complex molecular and cellular program 
in which epithelial cells shed their differentiated characteristics, including cell–cell adhesion, planar and api-
cal–basal polarity, and lack of motility. The epithelial cells instead acquire mesenchymal features, which include 
motility, invasiveness, and a heightened resistance to apoptosis42. Our aforementioned observations suggested 
that TrkC may be sufficient to induce EMT. To address whether TrkC is sufficient to induce EMT, we ectopically 
expressed TrkC in MCF10A breast cancer cells and Maden-Darby Canine Kidney (MDCK) epithelial cells, which 
have been widely used to study EMT in breast cancer12–14. As shown in Fig. 6a, MCF10A and MDCK control cells 
expressed high levels of E-cadherin, α -catenin, and β -catenin, but minimal levels of N-cadherin and fibronectin. 
However, MCF10A-TrkC and MDCK-TrkC cells downregulated the expression of E-cadherin, α -catenin, and 
β -catenin, but increased N-cadherin and fibronectin expression. Moreover, MDCK-TrkC cells downregulated the 
expression of mRNA levels encoding epithelial marker (E-cadherin) while upregulating mRNA levels encoding 
mesenchymal marker (N-cadherin) (Fig. 6b).
The loss of E-cadherin appears to be critical for EMT. One major mechanism for inhibiting E-cadherin expres-
sion involves silencing of E-cadherin transcription through three E-boxes in CDH-1 promoter43. To determine 
whether the loss of E-cadherin in the MDCK-TrkC cells was due to transcriptional repression by upregulated 
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TrkC, we transiently transfected MDCK-TrkC cells with an E-cadherin reporter construct. Indeed, luciferase 
activity was efficiently suppressed in MDCK-TrkC cells compared to that in MDCK control cells (Fig. 6c). At 
the biochemical level, E-cadherin protein disappeared from the cell membrane in MDCK-TrkC cells but was 
strongly stained in the control cells. In contrast, N-cadherin expression was strongly induced in MDCK-TrkC 
cells (Fig. 6d). Therefore, the molecular changes in TrkC-expressing MDCK cells indicated that these cells had 
undergone EMT.
The major mechanism underlying the loss of E-cadherin mRNA is direct transcriptional repression by 
the repressors SIP1, Slug, Goosecoid, E12, Snail, HMGA2, and Twist-1. These transcriptional repressors have 
been found to induce EMT in vitro, and their overexpression in a variety of human tumors is associated with 
increased tumor invasion, metastasis, and poor prognosis42,44. To test this, we examined the expression levels of 
SIP1, Goosecoid, Slug, and E12 in MDCK cells, but we found that the levels did not differ significantly between 
the MDCK control and MDCK-TrkC cells (Fig. 6e). However, expression and luciferase activity of Twist-1 and 
Twist-2 was significantly higher in MDCK-TrkC cells than MDCK control cells (Fig. 6f,g). These data indicate 
that TrkC is capable of inducing EMT through JAK2/STAT3/Twist cascade. Based on our previous observations, 
we speculated that TrkC might contribute to EMT and breast cancer progression. To test this notion, we next 
examined whether TrkC knockdown affected the ability of SUM149 and Hs578T cells to express Twist-1 and 
Twist-2. Quantitative RT-PCR analysis showed that the mRNAs encoding Twist-1 and Twist-2, which are master 
regulators of tumor metastasis and EMT, were markedly reduced in SUM149 and Hs578T TrkC-shRNA cells 
Figure 5. TrkC/c-Src or TrkC interacts with JAK2 and leads to Twist-1 upregulation through activation of 
the JAK/STAT3 pathway. (a) Western blot analysis of the expression of P-JAK2, JAK2, P-STAT3, STAT3, and 
Twist-1 proteins in Hs578T and SUM149 cells with or without 5 μ M SU6656 treatment for 6 hr. β -actin was used 
as a loading control. (b) TrkC or TrkC/c-Src complex interacts with JAK2. Immunoblot analysis of whole-cell 
lysates and immunoprecipitates derived from 293T cells transfected with the V5-TrkC, HA c-Src, and Myc-Jak2 
constructs as indicated. (c) Identification of complex formation of endogenous TrkC/c-Src/JAK2 in Hs578T 
and SUM149 cells. (d) TrkC interacts with JAK2 in SYF-TrkC cells or SYF-Src-TrkC cells after transfection 
with Myc-Jak2. (e) Activation and expression of Jak2 in SYF cells or SYF-TrkC cells after immunoprecipitation 
was examined by immunoblotting using the indicated antibodies. (f) Western blot analysis of the expression of 
P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in SYF cells or SYF-TrkC cells. (g) Western blot analysis 
of expression of P-JAK2, JAK2, P-STAT3, STAT3, and Twist-1 proteins in SYF, SYF-TrkC, SYF-cSrc, and SYF-
cSrc-TrkC cells. (h) Expression levels of mRNA encoding Twist-1 and Twist-2 in Hs578T control-shRNA 
or TrkC-shRNA cells with or without 5 μ M SU6656 treatment for 6 hr. 18S mRNA was used to normalize 
variability in template loading. Data are presented as mean ± standard error of the mean (SEM).
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relative to those in control-shRNA cells (Figure S7a). As shown in Figure S7b, we also observed that Twist-1- 
and Twist-2 luciferase activity was efficiently and identically suppressed in SUM149 and Hs578T TrkC-shRNA 
cells compared to that of SUM149 and Hs578T control-shRNA cells. Moreover, immunofluorescence staining 
demonstrated that Twist-1 expression was high in Hs578T control-shRNA cells but was markedly reduced in 
Hs578T TrkC-shRNA cells (Figure S7c). A recent study demonstrated that the Twist-1 transcription factor, which 
is a master regulator of embryonic morphogenesis, plays an essential role in metastasis14. Induction of EMT by 
Immortalized human mammary epithelial cells (HMLEs) stably expressing Twist and Snail acquire self-renewing 
traits associated with normal tissue (SCs) and cancer stem cells (CSCs)45. Moreover, similar to Twist-1, Twist-2 is 
overexpressed in a large variety of human primary tumors and cancer cell lines46. These data indicate that TrkC is 
capable of inducing EMT through upregulation of Twist-1 and Twist-2 expression.
We next examined whether the pharmacological inhibition of TrkC with K252a, an inhibitor of Trk tyros-
ine kinases, could influence the ability of Hs578T cells to survive and proliferate. Hs578T cells proliferated as 
large spheroid aggregates in suspension but demonstrated a significantly lower survival outcome in suspension 
after treatment with the Trk inhibitor K252a. Also, Hs578T and SUM149 TrkC-shRNA cells showed markedly 
lower survival than Hs578T and SUM149 control-shRNA cells in suspension (Figure S8a). These findings sug-
gest that TrkC affects Hs578T and SUM149 cell survival. We next examined whether the loss of TrkC expres-
sion affected the ability of Hs578T or SUM149 cells to proliferate in vitro. Hs578T and SUM149 TrkC-shRNA 
cells grew slower than Hs578T and SUM149 control-shRNA cells (Figure S8b). We also examined whether TrkC 
Figure 6. TrkC induces the EMT program by upregulating Twist. (a) Western blot analysis of the expression 
of TrkC, E-cadherin, α -catenin, β -catenin, N-cadherin, and fibronectin proteins in MCF10A and MDCK 
control or TrkC cells. β -actin was used as a loading control. (b) The expression levels of mRNA encoding 
E-cadherin and N-cadherin in MDCK or MDCK-TrkC cells. 18S mRNA was used to normalize variability in 
template loading. Data are presented as mean ± standard error of the mean (SEM). (c) Luciferase reporter assay 
of E-cadherin in MDCK or MDCK-TrkC cells. Each bar represents the mean ± SEM of three experiments. Data 
are presented as mean ± standard error of the mean (SEM). (d) Immunofluorescence staining of E-cadherin 
and N-cadherin in MDCK or MDCK-TrkC cells. The red signal represents the staining of the corresponding 
protein, while the blue signal represents DAPI nuclear DNA staining. (e,f) RT-PCR analysis of E12, Goosecoid, 
SIP1, or Slug mRNA levels (f) and immunoblotting analysis of Twist-1 levels (f) in MDCK or MDCK-TrkC 
cells. β -actin and GAPDH were used as loading controls. (g) Luciferase reporter assay of Twist-1 and Twist-2 
in MDCK or MDCK-TrkC cells. Each bar represents the mean ± SEM of three experiments. Data are presented 
as mean ± standard error of the mean (SEM). Some of the bar graphs do not have visible error bars due to low 
values of standard error of the mean (SEM).
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knockdown affected the anchorage-independent growth of breast cancer cells. After growing in soft agar for 
15 days, Hs578T control and SUM149 TrkC-shRNA cells formed a significantly lower number of colonies rel-
ative to that of the control (Figure S8c). To test for another functional hallmark of cancer, we conducted an 
in vitro motility assay and wound healing assays. Hs578T- and SUM149 control-shRNA cells showed increased 
cell motility, whereas Hs578T- and SUM149 TrkC-shRNA cells had low motility, indicating that the increased 
motility of cells was largely due to TrkC expression (Figure S8d,e). We next examined whether TrkC overex-
pression induces the metastatic potential of a non-metasizing breast cells. The capacity of the cell to migrate and 
invade was markedly reduced in MCF10A-TrkC kinase dead mutant cells (K572N, Yx3F), or MCF10A-TrkC 
cells treated with K252a had low motility (Figure S9a,b). Moreover, we examined whether TrkC overexpression 
enhances mammosphere-forming ability to acquirement of self-renewal trait associated with cancer stem cells 
(CSCs). MCF10A-TrkC cells significantly induced mammosphere-forming ability compared to the MCF10A and 
MCF10A kinase-dead mutant (K572N, Y3XF) cells or K252a treatment (Figure S9c).
TrkC is essential for primary tumor formation and metastasis of breast cancer. To determine 
the contribution of TrkC to primary tumor formation, we injected MCF10A-Ras, MCF10A-Ras-TrkC, Hs578T 
control-shRNA or TrkC-shRNA cells into the mouse mammary fat pads of BALB/c Nu/Nu mice and exam-
ined the resulting primary tumors 29 days or 47 days later. MCF10A-Ras-TrkC and Hs578T control-shRNA 
cells formed primary mammary tumors at identical rates, whereas the primary tumor formation of Hs578T 
TrkC-shRNA or MCF10A-Ras cells was markedly decreased (Fig. 7a–d). We next examined whether the phar-
macological inhibition of TrkC with LOXO-101 could influence the ability of Hs578T cells to tumor growth 
in vivo. LOXO-101, a highly selective inhibitor of Trk tyrosine kinase, showed dramatic clinical activity in patients 
with a variety of cancers in phase I trials and is underongoing multicenter phase II trials47. Tumor growth in vivo 
by LOXO-101 treatment was dramatically inhibited relative to that of diluent (control) (Fig. 7e,f). These results 
demonstrate that TrkC is required for primary tumor formation of breast cancer.
To determine whether the loss of TrkC expression affected the ability of Hs578T cells to metastasize, Hs578T 
control-shRNA or TrkC-shRNA cells were injected into the tail veins of BALB/c Nu/Nu mice, and their lungs were 
examined for metastases 35 days later. The average number of visible metastatic nodules was markedly reduced 
in mice injected with Hs578T TrkC-shRNA cells relative to that of mice harboring Hs578T control-shRNA cells 
(Fig. 7g,h). Moreover, histological analyses confirmed that the number of micrometastatic lesions was drastically 
reduced in the lungs of mice with Hs578T TrkC-shRNA cells (Fig. 7h).
We suspected that the presence of small numbers of nodules in the lungs of mice carrying Hs578T 
TrkC-shRNA cells was due to incomplete knockdown of TrkC. Therefore, we analyzed TrkC expression in the 
lungs of mice expressing Hs578T control-shRNA or TrkC-shRNA cells. Although the few metastatic nodules that 
eventually formed in the lungs of mice with Hs578T TrkC-shRNA retained TrkC expression, TrkC expression in 
the lungs of mice with Hs578T TrkC-shRNA cells was drastically lower than that of Hs578T control-shRNA cells 
(Fig. 7i and S10a). These results indicate that TrkC loss reduces both cell motility and the number of metastases 
in the lung.
The regulation of Twist expression by TrkC was also evaluated by immunohistochemistry of the lungs of mice 
containing Hs578T control-shRNA or TrkC-shRNA cells using a Twist-1 specific antibody. Interestingly, Twist-1 
expression was markedly reduced in the lungs of mice injected with Hs578T TrkC-shRNA cells compared to that 
of their control counterparts (Fig. 7i). Moreover, tumor cells expressed lower levels of Twist-1 and Twist-2 when 
isolated from the lungs of mice injected with Hs578T TrkC-shRNA cells rather than Hs578T control-shRNA cells 
(Figure S10b,c).
Discussion
In our previous work, TrkC was found to induce Twist-1 expression in breast cancer. However, the signaling 
mechanisms by which TrkC induces Twist-1 and Twist-2 have been unclear. Here, we found that TrkC was suffi-
cient for direct interaction with JAK2 and blocked SOCS3-induced JAK2 degradation, which resulted in stabili-
zation of JAK2 expression and induction of STAT3, as well as the upregulation of Twist-1 gene expression. SOCS3 
is a transcriptional target of STAT3 that promotes the proteasomal degradation of phosphorylated STAT3 in a 
negative feedback loop48–50. Moreover, tissue remodeling was dramatically accelerated in Socs3-deficient mam-
mary glands by activation and high levels of STAT351. Furthermore, activated STAT3 transcriptionally induces 
Twist, which plays an important role in promoting metastasis and CSC traits41,45,52. Overall, we identified a new 
molecular and functional network present in cancer metastasis that regulates and coordinates with TrkC.
Recent studies have demonstrated that both autocrine and paracrine signals of IL-6 secreted by basal-like 
breast cancers lead to poor clinical outcome of basal-like breast cancers, and maintenance of stem cell–like can-
cer cells. Moreover, the positive feedback loop of IL-6 by NF-κ B signaling is mediated by the activation of the 
JAK2/STAT3 and PI3K/AKT pathways, and triggers malignant features in mammosphere formation18,36–40. We 
hypothesized that the JAK2/STAT3 and PI3K/AKT pathways are activated in metastatic breast cancer cells due to 
IL-6 induction by TrkC and IL-6 subsequently activates an autocrine loop. We demonstrated that TrkC increases 
secretion and expression of IL-6, suggesting that these autocrine loops generated by TrkC may ensure mainte-
nance of the mesenchymal/CSC state by continued activation of the JAK2/STAT3 and PI3K/AKT pathways and 
upregulation of Twist expression.
In our previous work, c-Src activation by TrkC was found to induce activation of the PI3K-AKT pathway32. 
Moreover, activated c-Src has been shown to induce STAT3 activation and lead to a significant increase in the 
levels of Twist-1 and Twist-241. In addition, increased associations between c-Src and HER-2 contribute to tras-
tuzumab resistance53. Therefore, we investigated whether induction of Twist-1 depended on the activation of 
STAT3 via c-Src activation by TrkC. Our findings indicated that activated c-Src by TrkC induced Twist expression 
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through induction of JAK2 expression, but not STAT3 activation. Our study further demonstrated that TrkC was 
a key regulator in the induction of Twist-1 through activation of JAK2 and STAT3. Moreover, we demonstrated 
that TrkC is associated with JAK2/c-Src and induces JAK2/c-Src activation, resulting in increased phospho-JAK2/
STAT3 levels, which subsequently leads to Twist-1 upregulation. These observations suggest that TrkC can acti-
vate the JAK2/STAT3/Twist-1 axis directly and indirectly through c-Src.
Individual tumor cell invasion is a highly complicated process that requires malignant cells to, at minimum, 
obtain migration and dissemination properties to escape from the constraints of tissue structure54. We deline-
ated the role of TrkC in cancer malignancies. TrkC knockdown markedly suppressed survival in suspension and 
primary tumor formation while significantly reducing micrometastatic lesions in mice injected with Hs578T 
TrkC-shRNA cells. Our data suggest that TrkC is sufficient for tumorigenicity and metastasis of breast cancer 
cells. Moreover, these findings shed new light on the role of TrkC in metastasis and the possibility that molecular 
Figure 7. Suppression of TrkC expression inhibited the ability of Hs578T cells to metastasize from the 
mammary gland to the lung. (a) Volumes of primary mammary tumors formed by Hs578T control-shRNA or 
TrkC-shRNA cells. Each data point represents the mean of each type of primary tumor. A P < 0.0001 was considered 
to indicate significance for ANOVA. (b) Representative images of tumors from mice harboring Hs578T control-
shRNA or TrkC-shRNA mammary tumors after tumor implantation. (c) Volumes of primary mammary tumors 
formed by MCF10A-Ras or MCF10A-Ras-TrkC cells. Each data point represents the mean of each type of primary 
tumor. A P < 0.0001 was considered to indicate significance for ANOVA. (d) Representative images of tumors 
from mice harboring MCF10A-Ras or MCF10A-Ras-TrkC cells. (e) LOXO-101 inhibits tumor growth in a Hs578T 
xenograft model. 1 × 106 cells were implanted into the mammary fat pads of mice and treated with diluent (control) 
or LOXO-101 (60 mg/kg/dose) twice daily for 14 days when the tumor size was 200 ± 20 mm3. (f) Representative 
images of tumors from mice harboring diluent (control) or LOXO-101 (60 mg/kg/dose) (g) Total number of lung 
metastatic nodules in each mouse in each group were counted using a dissection scope. Two populations of Hs578T 
cells that were independently infected with TrkC-shRNA #1 and TrkC-shRNA #2 were used in independent 
experiments (n = 6) and consistently yielded similar results. A P < 0.0001 was considered to indicate significance for 
ANOVA. (h) Representative images and H&E staining sections of mouse lung lobes 35 days after tail vein injection 
of Hs578T control-shRNA or TrkC-shRNA cells. N, Normal lung tissue; M, metastatic nodule. (i) Immunoblotting 
of the expression of TrkC and Twist-1 in tumor cells recovered from the lungs of individual mice expressing either 
Hs578T control-shRNA or TrkC-shRNA. Some of the bar graphs do not have visible error bars due to low values of 
standard error of the mean (SEM).
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components of TrkC signaling pathways are potential candidates for future investigations, due to their possible 
involvement in tumor metastasis.
Taken together, we dissected the role of TrkC in EMT by gain-of-function ectopic TrkC overexpres-
sion. A number of studies suggest that carcinoma cells often activate EMT to acquire the ability to exe-
cute multiple steps of the invasion-metastasis cascade. EMT-mediated invasion has also been largely 
attributed to the loss of E-cadherin, a tumor invasion suppressor. In addition, EMT has been associ-
ated with cancer stem cell traits, suggesting a role of EMT in the initiation of recurrent tumors from dis-
seminated cancer cells3,42,45,55. In this study, we demonstrated that TrkC plays a critical role in EMT. Indeed, 
during the induction of EMT, we observed activation of EMT-inducing transcription factors, notably 
Twist-1 and Twist-2. Increased Twist-1 and Twist-2 expression is found in various human cancers, includ-
ing melanoma, T-cell lymphoma, rhabdomyosarcoma, and gastric carcinomas56–58. Additionally, Twist-1 
and Twist-2 proteins override oncogene-induced premature senescence by abrogating key regulators of 
the p53- and Rb-dependent pathways. Moreover, in epithelial cells, the oncogenic cooperation between 
Twist proteins and activated mitogenic oncoproteins such as Ras and ErbB2 lead to complete EMT14,15,46. 
Furthermore, induction of EMT by Twist-1 induces and maintains stem cell states in breast cancer45,52. 
Our findings suggest that TrkC-induced EMT can contribute to the invasion and metastasis phenotypes.
Metastatic breast cancers enhances chemoresistance through upregulation of EMT markers and exhibit 
a CD44high/CD24low antigenic phenotype with stem cell-like characteristics (CSCs). Activation of the PI3K/
AKT pathway, IL-6/JAK2/STAT3 pathway, and stem cell-like characteristics contribute to the poor outcomes 
of metastatic breast cancers1,18. Therefore, it is likely that TrkC regulates the activity of JAK2/STAT3/Twist-1 
and PI3K/AKT to generate relatively unlimited numbers of cancer stem cells, and to induce the metastatic 
potential of cancer cells through the induction of EMT (Figure S10). In addition, the inhibition of TrkC kinase 
activity may have a notable impact on the tumorigenic and metastatic capacities of highly metastatic breast 
cancers. Accordingly, the role of TrkC in the development and progression of human breast cancer deserves 
further attention.
Materials and Methods
All methods carried out in this manuscript were approved by Institutional Biosafety Committee and Institutional 
Animal Care and Use Committee (IACUC) of the Gachon University. In addition to this, all experiments were 
performed in accordance with the approved regulations and guidelines.
Cell culture and reagents. Human breast cancer cells (Table S2), SYF, 293T, and MDCK cells were pur-
chased from American Type Culture Collection (Manassas, VA, UDA); SUM149 breast cells were obtained from 
Dr. Stephen Ethier (Kramanos Institute, MI, USA) and were maintained as described previously14,59. K252a, 
MG-132, SU6656, and AG490 were purchased from Calbiochem.
Human breast tumor samples. RNA of normal and tumorous human breast samples were obtained from 
the Gangnam Severance Hospital after approval by the institutional review board and the ethics committee of 
Gangnam Severance Hospital (IRB approval number: 3-2011-0191).
Plasmids. Each of the two shRNA-encoding oligonucleotides against human TrkC and c-Src were designed 
and verified to be specific to TrkC and c-Src by BLAST searches against the mouse and human genomes, respec-
tively. The primers corresponding to shRNA against TrkC and c-Src were cloned into the pLKO lentiviral vector 
to generate the TrkC-shRNA expression plasmid (Table S3). A control shRNA that did not match any known 
mouse- or human-coding cDNA was used as a control.
Antibodies, western blotting, immunoprecipitation, and immunofluorescence. We per-
formed western blotting, immunoprecipitation, and immunofluorescence analysis as previously described33. 
Anti-IL-6 neutralizing antibody (mabg-hil6-3) was from InvivoGen; Anti-HA (SC-805), anti-TrkC (SC-
117), and anti-Myc (SC-40) were from Santa Cruz Biotechnology; anti-V5 (R960-CUS) was from Invitrogen; 
anti-SOCS3 (ab16030), anti-JAK2 (ab108596), anti-Twist-1 (ab50887), and anti-phosphotyrosine (ab10321) 
were from Abcam; anti-STAT3 (9139), anti-phospho-STAT3 (4113), and anti-phospho-JAK2 (3771) were from 
Cell Signaling Technology; and anti-E-cadherin (610405), anti-fibronectin (610078), anti-N-cadherin (610920), 
anti-alpha-catenin (610194), and anti-beta-catenin (610154) were from BD Transduction.
Soft agar assays, wound healing assays, anchorage-independent cell growth, viral production, 
reverse transcription PCR, and matrigel invasion assays. All of the assays were performed as previ-
ously described33,54. The primer sequences used to amplify the genes are listed in the supplemental experimental 
procedures (Table S4).
Quantitative RT-PCR. The primer sequences are listed in the supplemental experimental procedures (Table S4). 
Total RNA was isolated using RNeasy Mini Kits (Qiagen) according to the manufacturer’s instructions and reverse 
transcribed with Hexa-nucleotide Mix (Roche). The resulting cDNA was subjected to PCR using the SYBR-Green 
Master PCR mix and the Taqman master PCR mix (Applied Biosystems) in triplicate. PCR and data collection 
were performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems). All quantitations were 
normalized to the endogenous control 18S RNA. Specific TrkC (Hs00176797_m1) and 18S (Hs99999901_s1) 
quantitative probes for Taqman RT-PCR were obtained from Applied Biosystems.
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Luciferase reporter assay. Cells that were 50% confluent in 12-well dishes were transfected using 
Lipofectamine 2000 (Invitrogen). A total of 0.5 μ g E-cadherin, Twist-1, Twist-2, or STAT3 reporter gene constructs 
and 0.5 μ g of pCMV-β -gal were cotransfected per well. The cell extracts were prepared 48 hrs after transfection, and 
luciferase activity was quantified using the Enhanced Luciferase Assay Kit (BD Biosciences). All of the experiments 
were performed in triplicate.
ELISA assay. Equal numbers of Hs578T control-shRNA or Hs578T TrkC-shRNA cells were plated and cul-
tured for 3 days. Subsequently, conditioned media from these cell cultures were collected and analyzed by the 
Human IL-6 Quantikine ELIZA kit (R&D systems) according to the manufacturer’s instructions.
Microarray data analysis. TrkC and Twist-1 levels in 2,136 breast cancer patients of the Curtis database34 
and 158 breast cancer patients of the Gluck database60 were extracted and averaged. ANOVA was performed 
and boxplot graphs were plotted with gene expression using GraphPad Prism v 5.0 (GraphPad Software, Inc.). A 
P < 0.0001 was considered to indicate significance.
Animal studies. Animal studies were performed as previously described33. Female BALB/c Nu/Nu mice 
(7 weeks old) were purchased from the Korea Research Institute of Bioscience and Biotechnology (KRIBB, South 
Korea) and handled in compliance with protocols approved by the Institutional Animal Care and Use Committee 
(IACUC) of Gachon University (Approval No. LCDI-2012-0016). For tumorigenicity studies, Hs578T (1 × 105), 
MCF10A-Ras (1 × 106), or MCF10A-Ras-TrkC (1 × 106) cells suspended in 50μ l PBS/Matrigel (BD Biosciences) 
were injected subcutaneously into the left and right hind flank regions under anesthesia. Mice were euthanized 
at indicated days, and primary tumors were excised for analysis. For tail-vein injection, 1 × 105 cells suspended 
in 50μ l PBS were injected into the tail vein of 7-week-old female BALB/c Nu/Nu mice. For tumor inhibition by 
LOXO-101 (Active Biochem), Hs578T cells (1 × 106) were injected subcutaneously into the dorsal flank area of 
the mice. Once tumors were established and reached a size of 200 ± 20 mm3, LOXO-101 (60 mg/kg/dose) was 
administrated by oral gavage twice daily for 14 days.
Statistical analysis. Data are expressed as the mean ± SEM. Statistical analyses of data were conducted 
via Student’s t test (two-tailed) and ANOVA. Differences were considered statistically significant at P < 0.05 or 
P < 0.0001.
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